Comparison of porcine anti-human lymphocyte globulin and rabbit anti-human thymocyte globulin in the treatment of severe aplastic anemia: a retrospective single-center study.
To compare the safety and efficacy of porcine antilymphocyte globulin (pALG) and rabbit antithymocyte globulin (rATG) in treating severe aplastic anemia (SAA). Seventy-seven patients with SAA that received immunosuppressive therapy between July 2004 and December 2013 at the Department of Hematology, the Second Affiliated Hospital of Xi'an Jiaotong University, were retrospectively analyzed. Forty-five patients received treatment including pALG (pALG group), and 32 patients received treatment including rATG (rATG group). Effective treatment rates between the two groups 1 yr after the treatment were compared; Kaplan-Meier 5-yr survival curve and log-rank test compared survival rates between the groups. All adverse responses were recorded. The 1-yr overall response rate in the pALG group (83.78%) was significantly higher than that in the rATG group (66.67%, P = 0.036), and the 5-yr overall survival rate in the pALG group (82.22%) was also higher than that in the rATG group (68.75%), but the difference was not statistically significant (P = 0.32). The incidence of adverse events was similar in the two groups, and no treatment-related deaths occurred. The efficacies, survival, and safety profiles of pALG-based treatments are similar to or even better than those of rATG-based treatments. These results may help guide the clinical use of pALG in immunosuppressive therapy for SAA.